December 9, 2013

Salk Institute Board of Trustees elects two visionary business leaders

Salk News


Salk Institute Board of Trustees elects two visionary business leaders

LA JOLLA, CA—The Salk Institute is pleased to announce that Alan D. Gold and David F. Hale have been elected to its Board of Trustees.

“Alan and David each bring outstanding records of entrepreneurial success and business expertise to Salk,” said Irwin M. Jacobs, Chairman of the Salk Institute Board of Trustees. “We are greatly pleased to have them join our Board of Trustees.”

Alan D. Gold is chairman and chief executive officer of Biomed Realty, a publicly traded REIT specializing in acquiring and managing laboratory properties for lease to the life science industry. Mr. Gold also served as president of BioMed’s privately held predecessor, Bernardo Property Advisors, Inc. He was a co-founder and served as president and as a director of Alexandria Real Estate Equities, Inc. He was managing partner of GoldStone Real Estate Finance and Investments, a partnership engaged in the real estate and mortgage business. He also served as assistant vice president of Commercial Real Estate for Northland Financial Company, a full service commercial property mortgage banker, and as Real Estate Investment Officer – Commercial Real Estate for John Burnham Company, a regional full service real estate company. He currently serves on the Campanile Foundation Board supporting San Diego State University.

David F. Hale is chairman and chief executive officer of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He also serves as executive chairman of Biocept, Inc., a cancer diagnostic company working on the detection and analysis of circulating tumor cells. Previously, he was president and chief executive officer of CancerVax Corporation from October 2000 through its merger in May 2006 with Micromet, Inc. where he served as chairman until its acquisition by Amgen Inc. in 2012. Additionally, Mr. Hale is chairman of Santarus, Inc., and a founding director and chairman of Conatus Pharmaceuticals, Inc. He is a co-founder and chairman of numerous other companies. Mr. Hale currently serves on the board of directors of BIOCOM, which he co- founded, and the San Diego Economic Development Corporation. He is a former member of the board of the Biotechnology Industry Organization (BIO) and the Biotechnology Institute. He is a co-founder and a director of CONNECT, acts as chairman of the board of trustees of Rady Children’s Hospital, and is a member of Rady School of Management Dean’s Advisory Council.


About the Salk Institute for Biological Studies:

The Salk Institute for Biological Studies is one of the world’s preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer’s, diabetes and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.

Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.

For More Information

Office of Communications
Tel: (858) 453-4100
press@salk.edu